Drug discovery is a complex process that involves identifying and developing new drugs to treat a wide range of diseases. It is a time-consuming and expensive process that can take years to complete. However, recent advancements in technology have made it possible to accelerate drug discovery and development, and Visikol Inc. is at the forefront of this revolution.
Liver Fibrosis Assay
One of the most exciting services offered by Visikol is their Liver Fibrosis Assay. This assay is an in vitro model for the development of therapeutics to prevent or treat liver fibrosis, a condition that affects a large percent of the population and can lead to liver damage and cirrhosis. Visikol’s Liver Fibrosis Assay uses 3D cell culture models that incorporate a mixture of hepatocytes or hepatocyte-like cells with nonparenchymal cells (NPCs) to provide the greatest utility. The assay analyzes gene expression via qPCR, allowing for many genes of interest to be evaluated using a single sample.
Visikol’s approach to 3D cell culture model analysis is unique in that it processes individual Z slices instead of extrapolating data from Z projections, which allows for the entire population of cells to be characterized. They also offer true 3D analysis services wherein every cell within a 3D cell culture model can be characterized. Additionally, Visikol provides comprehensive reports that distill the data to its essential components, giving actionable insights about the experiment.
High Content Screening
High Content Screening (HCS) is another valuable tool offered by Visikol. It allows for the interrogation and quantitation of cellular response of disease models to treatments, stimuli, or alterations in protein expression. It delivers richer datasets than traditional assays, since this approach allows for assessing multiple endpoints simultaneously at a cellular resolution. The use of imaging-based endpoints allows for examination of the specific effect of compound treatments on specific sub-populations of cells, as well as providing access to more complex measurements than can be accomplished with traditional assay formats. Combining these data with in-house machine-learning and informatics expertise, HCS delivers comprehensive reports that distill the data to its essential components, giving actionable insights about the experiment.
Visikol’s Liver Fibrosis Assay is a valuable tool for researchers looking to accelerate drug discovery and development. The assay provides a comprehensive analysis of gene expression and cellular response to treatments, allowing researchers to identify potential drug candidates quickly and efficiently. Additionally, Visikol’s quality control process ensures standardization of their liver assays, providing reliable and reproducible results.
Drug discovery is a complex process that requires the use of advanced technologies and techniques to accelerate the development of new therapeutics. Visikol Inc. offers a range of contract research services that can aid in drug discovery and development, including their Liver Fibrosis Assay. This assay uses 3D cell culture models, high content screening, and advanced imaging and image analysis technologies to provide a comprehensive analysis of gene expression and cellular response to treatments. Visikol’s unique approach to drug discovery is helping to revolutionize the field and accelerate the development of new therapeutics. To learn more about Visikol’s Liver Fibrosis Assay, please reach out to a member of our team today!